Promising results of HIV prevention trials highlight the benefits of collaboration in global health: The perspective of the Forum HIV Recency Assay Working Group
Year: 2024
Type: article
Abstract: Twelve years ago, in 2012, the US Food and Drug Administration (FDA) approved oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) as pre-exposure prophylaxis (PrEP) for HIV prevention.In 2015, the World Health Organization (WHO) recommended offering oral PrEP to all people at substantial HIV risk.In 2023, there were 3.5 million PrEP users globally [1], up from 600,000 users in 2019 [2].However, progress varies significantly across regions, countries, and populations, and further increases are needed to meet the 21.2 million PrEP user target by the end of 2025 [1].Only Eastern and Southern Africa is on track to meet its target of 3.6 million users (2.4 million in 2023).Furthermore, in 2023, 1.3 million people acquired HIV globally [1], underscoring the ongoing need to improve access to prevention options and develop new products that align with user needs and preferences.In this article, we argue that collaboration between diverse stakeholders is necessary to address critical issues in the HIV response and advance global health (Box 1).
Source: PLOS Global Public Health
Authors: Robin Schaefer, Logan Donaldson, Mitchell Leus, Chukwunomso E. Osakwe, Benjamin Chimukangara, Shona Dalal, Ann Duerr, Fei Gao, David V. Glidden, Beatriz Grinsztejn, Jessica Justman, Grace Kumwenda, Oliver Laeyendecker, Ha Youn Lee, Frank Maldarelli, Kenneth H. Mayer, Jeffrey Murray, Bharat S. Parekh, Brian Rice, Michael N. Robertson, Suzue Saito, Vani Vannappagari, Mitchell Warren, Diana Zeballos, Jörg Zinserling, Veronica Miller
Institutions: University of California, Berkeley, National Institutes of Health, World Health Organization, Fred Hutch Cancer Center, University of California, San Francisco, Fundação Oswaldo Cruz, ICAP Global Health, National Institute of Allergy and Infectious Diseases, University of Southern California, National Cancer Institute, Beth Israel Deaconess Medical Center, Harvard University, Fenway Health, Centers for Disease Control and Prevention, University of Sheffield, Universidade Federal da Bahia, Federal Institute for Drugs and Medical Devices
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,400
OpenAlex ID: W4403708043